Global Calcium Channel Blocker Market, By Drug Class (Dihydropyridine, Benzothizepine, Phenylalkylamine, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Calcium Channel Blocker Market Analysis and Size
The growing incidence rate of cardiovascular diseases and the rising changing lifestyle of people are anticipated to boost the calcium channel blocker market growth. Numerous research studies have been distributed to provide information about the calcium channel blockers. In addition to this, several new advances in the treatment options and the huge presence of well-established healthcare facilities are some of the major impacting factors for the demand for these blockers. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the calcium channel blocker market in the forecast period 2023-2030. The expected CAGR of calcium channel blocker market is tend to be around 6.5% in the mentioned forecast period. The market value is USD 14.91 billion in 2022, and it is expected to grow upto USD 24.68 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Calcium Channel Blocker Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug Class (Dihydropyridine, Benzothizepine, Phenylalkylamine, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Bausch Health (Canada), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Sun Pharmaceutical Industries Ltd (India), Novartis AG (U.S.), Zydus group (India), Pfizer Inc (U.S.), Lupin (India), GSK Plc (U.K.), Sofgen (U.S.), Glenmark Pharmaceuticals Inc (India), Amneal Pharmaceuticals (U.S.), Covis Pharma GmbH (Switzerland)
|
|
Market Opportunities
|
|
Market Definition
Calcium channel blockers, often called calcium antagonists, are prescription pharmaceuticals drugs widely used for the treatment of heart disorders such as angina, high blood pressure, arrhythmias, and other blood disorders particularly several circulatory disorders. These blockers work by inhibiting voltage-gated calcium channels, which in turn causes calcium restriction into cardiac and smooth muscle cells.
Calcium Channel Blocker Market Dynamics
Drivers
- Increase in Cardiovascular Diseases
As per the records of the WHO, about 60% - 85% of population have adopted a sedentary life. As per CDC, about 31 million adults aged over 50 years lives a sedentary and unhealthy lifestyle, and only 1 out of 4 U.S. adults meets the proper need of physical activity. Also, hypertension is one of the other reasons as well. In August 2021, according to a news releaseBoehringer Ingelheim GmbH issues, heart failure is a chronic, incapacitating cardio-renal-metabolic disease that affects around 60 million individuals or more globally. As the occurrence of heart failure continues to increase, new therapeutic options are desperately needed. Therefore, these increases the demand for these blockers and boost the market growth.
- Increasing Demand for Oral Drugs
Oral drugs is anticipated to boost the market growth. The segment is anticipated to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.
Opportunities
- Increased Clinical Studies and Government Initiatives
Increasing awareness about the channel blockers and studies that are mainly conducted for the development in identifying the diseases that by government and private organizations for better knowledge of these blockers is most likely to drive the market growth. For instance, as per a research study published in May 2022 titled "Calcium channel blockers potentiate gemcitabine chemotherapy in pancreatic cancer," calcium channel blockers (CCBs) such as amlodipine considerably increased the therapeutic responses to gemcitabine in orthotopic xenografts and transgenic models of pancreatic ductal adenocarcinoma by restrciting prosurvival epidermal growth factor receptor (EGFR) signalling in vitro (PDAC).
- Increasing Demand for Retail Pharmacies
Increase in the number of calcium channel blockers delivered through the retail pharmacies and rise in the number of retail pharmacies in highly developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily available.
Restraints/Challenges
- Lack of skilled professionals
The lack of qualified personnel who are unable to the cardiovascular patients with these channel blockers appropriately could restrain the growth of the global calcium channel blocker market over a forecast period.
- High Cost of Treatment
The huge expenditure associated with these calcium channel blockers hamper the market growth. The channel blockers are quite high priced and not everyone from the lower economic groups can afford these blockers.
This calcium channel blocker market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the calcium channel blocker market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Calcium Channel Blocker Market
The pandemic had a major effect on the market growth. For instance, the research study named "Anxiety, home blood pressure monitoring, and cardiovascular events among older hypertension patients during the COVID-19 pandemic" published in January 2022 stated that anxiety associated with the COVID-19 pandemic is associated to a temporary rise in the home morning sleep blood pressure (SBP) among older patients and rises the risk of cardiovascular events over the course of the 1-year follow-up. Continuous blood pressure monitoring is essential both during and after the pandemic, which will increase the market for calcium channel blockers to rise over the future years to maintain blood pressure stability among the diagnosed population.
Global Calcium Channel Blocker Market Scope
The calcium channel blocker market is segmented on the basis of drug class, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Class
- Dihydropyridine
- Benzothizepine
- Phenylalkylamine
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Calcium Channel Blocker Market Regional Analysis/Insights
The calcium channel blocker market is analyzed and market size insights and trends are provided by drug class, distribution channel and end-user as referenced above.
The major countries covered in the calcium channel blocker market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been witnessing a positive growth for calcium channel blocker market throughout the forecasted period because of the high incidence of poison cases and increase in research and development activities for antidotes.
Asia-Pacific dominates the market because of the developing healthcare facilities, large number of generic manufacturers and increase in government initiatives and specialist communities.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Calcium Channel Blocker Market Share Analysis
The calcium channel blocker market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to calcium channel blocker market.
Key players operating in the calcium channel blocker market include:
- Bausch Health (Canada)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd (Israel)
- Sun Pharmaceutical Industries Ltd (India)
- Novartis AG (U.S.)
- Zydus Group (India)
- Pfizer Inc (U.S.)
- Lupin (India)
- GSK Plc (U.K.
- Sofgen (U.S.)
- Glenmark Pharmaceuticals Inc (India)
- Amneal Pharmaceuticals (U.S.)
- Covis Pharma GmbH (Switzerland)
SKU-